Real-World Six- and Twelve-Month Drug Retention, Remission, and
Response Rates of Secukinumab in 2,017 Patients With Psoriatic
Arthritis in Thirteen European Countries

J 2022

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

MICHELSEN, Brigitte, Stylianos GEORGIADIS, Di Giuseppe DANIELA, Anne G LOFT, Michael J NISSEN et. al.

Základní údaje

Originální název

Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Autoři

Vydání

ARTHRITIS CARE & RESEARCH, HOBOKEN, WILEY, 2022, 2151-464X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30226 Rheumatology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.700

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/acr.24560

UT WoS

000788811100001

Klíčová slova anglicky

Psoriatic Arthritis

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 7. 2024 09:53, Mgr. Tereza Miškechová

Anotace

V originále

Objective There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. Methods Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. Results A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (4 years), and varied significantly across the European registries. Conclusion In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.

Citovat

MICHELSEN, Brigitte, Stylianos GEORGIADIS, Di Giuseppe DANIELA, Anne G LOFT, Michael J NISSEN, Florenzo IANNONE, Manuel POMBO-SUAREZ, Herman MANN, Ziga ROTAR, Kari K EKLUND, Tore K KVIEN, Maria J SANTOS, Bjorn GUDBJORNSSON, Catalin CODREANU, Sema YILMAZ, Johan K WALLMAN, Cecilie H BRAHE, Burkhard MOELLER, Ennio G FAVALLI, Carlos SANCHEZ-PIEDRA, Lucie NEKVINDOVÁ, Matija TOMSIC, Nina TROKOVIC, Eirik K KRISTIANSLUND, Helena SANTOS, Thorvardur J LOVE, Ruxandra IONESCU, Yavuz PEHLIVAN, Gareth T JONES, Van der Horst-Bruinsma IRENE, Lykke M ORNBJERG, Mikkel OSTERGAARD a Merete L HETLAND. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. ARTHRITIS CARE & RESEARCH. HOBOKEN: WILEY, 2022, roč. 74, č. 7, s. 1205-1218. ISSN 2151-464X. Dostupné z: https://dx.doi.org/10.1002/acr.24560.

@article{2417962,
   author = {Michelsen, Brigitte and Georgiadis, Stylianos and Daniela, Di Giuseppe and Loft, Anne G and Nissen, Michael J and Iannone, Florenzo and PomboandSuarez, Manuel and Mann, Herman and Rotar, Ziga and Eklund, Kari K and Kvien, Tore K and Santos, Maria J and Gudbjornsson, Bjorn and Codreanu, Catalin and Yilmaz, Sema and Wallman, Johan K and Brahe, Cecilie H and Moeller, Burkhard and Favalli, Ennio G and SanchezandPiedra, Carlos and Nekvindová, Lucie and Tomsic, Matija and Trokovic, Nina and Kristianslund, Eirik K and Santos, Helena and Love, Thorvardur J and Ionescu, Ruxandra and Pehlivan, Yavuz and Jones, Gareth T and Irene, Van der HorstandBruinsma and Ornbjerg, Lykke M and Ostergaard, Mikkel and Hetland, Merete L},
   article_location = {HOBOKEN},
   article_number = {7},
   doi = {http://dx.doi.org/10.1002/acr.24560},
   keywords = {Psoriatic Arthritis},
   language = {eng},
   issn = {2151-464X},
   journal = {ARTHRITIS CARE & RESEARCH},
   title = {Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries},
   url = {https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24560},
   volume = {74},
   year = {2022}
}

TY  - JOUR
ID  - 2417962
AU  - Michelsen, Brigitte - Georgiadis, Stylianos - Daniela, Di Giuseppe - Loft, Anne G - Nissen, Michael J - Iannone, Florenzo - Pombo-Suarez, Manuel - Mann, Herman - Rotar, Ziga - Eklund, Kari K - Kvien, Tore K - Santos, Maria J - Gudbjornsson, Bjorn - Codreanu, Catalin - Yilmaz, Sema - Wallman, Johan K - Brahe, Cecilie H - Moeller, Burkhard - Favalli, Ennio G - Sanchez-Piedra, Carlos - Nekvindová, Lucie - Tomsic, Matija - Trokovic, Nina - Kristianslund, Eirik K - Santos, Helena - Love, Thorvardur J - Ionescu, Ruxandra - Pehlivan, Yavuz - Jones, Gareth T - Irene, Van der Horst-Bruinsma - Ornbjerg, Lykke M - Ostergaard, Mikkel - Hetland, Merete L
PY  - 2022
TI  - Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
JF  - ARTHRITIS CARE & RESEARCH
VL  - 74
IS  - 7
SP  - 1205-1218
EP  - 1205-1218
PB  - WILEY
SN  - 2151464X
KW  - Psoriatic Arthritis
UR  - https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.24560
N2  - Objective There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. Methods Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. Results A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (4 years), and varied significantly across the European registries. Conclusion In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.
ER  -

MICHELSEN, Brigitte, Stylianos GEORGIADIS, Di Giuseppe DANIELA, Anne G LOFT, Michael J NISSEN, Florenzo IANNONE, Manuel POMBO-SUAREZ, Herman MANN, Ziga ROTAR, Kari K EKLUND, Tore K KVIEN, Maria J SANTOS, Bjorn GUDBJORNSSON, Catalin CODREANU, Sema YILMAZ, Johan K WALLMAN, Cecilie H BRAHE, Burkhard MOELLER, Ennio G FAVALLI, Carlos SANCHEZ-PIEDRA, Lucie NEKVINDOVÁ, Matija TOMSIC, Nina TROKOVIC, Eirik K KRISTIANSLUND, Helena SANTOS, Thorvardur J LOVE, Ruxandra IONESCU, Yavuz PEHLIVAN, Gareth T JONES, Van der Horst-Bruinsma IRENE, Lykke M ORNBJERG, Mikkel OSTERGAARD a Merete L HETLAND. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. \textit{ARTHRITIS CARE \&{} RESEARCH}. HOBOKEN: WILEY, 2022, roč.~74, č.~7, s.~1205-1218. ISSN~2151-464X. Dostupné z: https://dx.doi.org/10.1002/acr.24560.

Podrobný výpis o publikaci